Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

At-Home kidney care: new study lets diabetes patients test drugs without leaving the house

NCT ID NCT06094920

First seen Feb 16, 2026 · Last updated Jun 15, 2026 · Updated 15 times

Summary

This study tested whether people with type 2 diabetes and kidney damage can safely participate in a clinical trial from home. Twelve participants took the drug empagliflozin, and depending on their response, some added or switched to finerenone. The goal was to see if remote data collection (urine, blood pressure, weight) is practical and to find the best personalized treatment to lower protein in the urine.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ZorgGroep Twente

    Almelo, Overijssel, 7609PP, Netherlands

Conditions

The condition(s) this trial relates to.

Albuminuria chronic kidney disease chronic renal failure syndrome Diabetes Complications diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.